Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

J.M. Ferreri, Andrés; Cwynarski, Kate; Jacobsen Pulczynski, Elisa; Ponzoni, Maurilio; Deckert, Martina; S. Politi, Letterio; Torri, Valter; P. Fox, Christopher; La Rosée, Paul; Schorb, Elisabeth; Ambrosetti, Achille; Röth, Alexander; Hemmaway, Claire; Ferrari, Angela; Linton, Kim; Rudà, Roberta; Binder, Mascha; Pukrop, Tobias; Balzarotti, Monica; Fabbri, Alberto; Johnson, Peter; Sønderskov Gørløv, Jette; Heß, Georg; Panse, Jens; Pisani, Francesco; Tucci, Alessandra; Stilgenbauer, Stephan; Hertenstein, Bernd; Keller, Ulrich; W. Krause, Stefan; Levis, Alessandro; Schmoll, Hans‐Joachim; Cavalli, Franco; Finke, Jürgen; Reni, Michele; Zucca, Emanuele; Illerhaus, Gerald

doi:10.1016/s2352-3026(16)00036-3

Public

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Published in The Lancet Haematology • Apr 9, 2016

Authors:

Andrés J.M. Ferreri

Kate Cwynarski

Elisa Jacobsen Pulczynski

Abstract

BACKGROUND: Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to...

Subject

Medicine

Rituximab

Chemoimmunotherapy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!